Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

Amini: They play a significant role in how we treat metastatic lung cancer. All patients with stage IV disease should have ...

A large CT imaging study identifies many clues which are the key risk factors linked to fast-growing lung cancer, supporting ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

It’s the third most common cancer in the UK, causing tens of thousands of deaths annually. But what if the disease, often only diagnosed when it’s too late, could be stopped before it even begins?

The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient ...

Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...